Remdesivir

🧮 Dose calculator

COVID-19 · Regimen source: FDA Veklury · 2.3

• • Hospitalised without ventilation: 5 days (up to 10 if no improvement); ventilation/ECMO: 10 days. Liver tests and PT before starting. No renal adjustment. FDA Veklury · 2.3FDA Veklury · 2.2FDA Veklury · 2.4

Enter age and weight.

👥 Special populations

• 🤰 PregnancyUse with caution

  Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Veklury · 8.1

  “Risk Summary Available data from a clinical trial (IMPAACT 2032), published reports, the COVID-PR pregnancy exposure registry, and compassionate use of remdesivir in pregnant individuals have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes following …”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Veklury · 8.2

  “Risk Summary A published case report describes the presence of remdesivir and active metabolite GS-441524 in human milk.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Veklury · 8.4

  “The safety and effectiveness of VEKLURY for the treatment of COVID-19 have been established in pediatric patients from birth to less than 18 years of age and weighing at least 1.5 kg, who are: Hospitalized, or Not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, …”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Veklury · 8.5

  “In general, appropriate caution should be exercised in the administration of VEKLURY and monitoring of elderly patients, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.”

• ⚥ Females & males of reproductive potentialNo data

  The source for this drug has no section for this group.